Vir Biotechnology Inc reports results for the quarter ended in March - Earnings Summary

Vir Biotechnology

03/05/2024 10:28

* Vir Biotechnology Inc  VIR.OQ  reported a quarterly
adjusted
loss of 48 cents​​ per share for the quarter ended in March,
higher than the same quarter last year, when the company
reported EPS of $-1.06.  The mean expectation of seven analysts
for the quarter was for a loss of $1.05 per share. Wall Street
expected results to range from $-1.32 to -79 cents per share.
    * Revenue fell 10.5% to $56.38 million from a year ago;
analysts
expected $11.71 million. 
    * Vir Biotechnology Inc's reported EPS for the quarter was a
loss
of 48 cents​.
    * The company reported a quarterly loss of $65.28 million.
    * Vir Biotechnology Inc shares had fallen by 9.4% this
quarter and
lost 8.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 4.2%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Vir Biotechnology
Inc is $20.00 
This summary was machine generated from LSEG data May 3 at 09:28
a.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -1.05          -0.48          Beat
 Dec. 31 2023      -1.01          -0.86          Beat
 Sep. 30 2023      -1.21          -1.22          Missed
 Jun. 30 2023      -1.20          -1.45          Missed